Commercial code

Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022

Retrieved on: 
Monday, May 23, 2022
Technology, Medical Devices, Other Technology, Clinical Trials, Software, Other Health, Biotechnology, Radiology, Health, Oncology, Cancer, Exercise, Balo concentric sclerosis, Patient, Cave rescue, View, Solution, Lists of diseases, Bulletin, Commercial code, BPI, Proxy, Valbonne, SME, Diagnosis, Artificial intelligence, Security (finance)

The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo 75116 Paris.

Key Points: 
  • The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo 75116 Paris.
  • All useful information relating to this Shareholders General Meeting is regularly updated on Median Technologies website.
  • Shareholders may exercise their voting rights before the holding of the Shareholders General Meeting, either by returning their postal voting form, or by giving proxy.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

DGAP-News: Formycon Publishes Annual Financial Statements for the 2021 Financial Year

Retrieved on: 
Thursday, May 19, 2022
AG, Diabetes, HGB, EBITDA, International, Regulation of tobacco by the U.S. Food and Drug Administration, Depreciation, Food, ISIN, FYB, European Medicines Agency, Regeneron Pharmaceuticals, Patient, Investment, Mission statement, Tax, Euro, COVID-19, Consolidated, Marketing, Patent, FDA, Johnson & Johnson, Gesellschaft mit beschränkter Haftung, Commercial code, EMA, Multiple sclerosis, Genentech, KG, Rheumatoid arthritis, Group, IFRS, EBIT, MedImmune, Inc. v. Genentech, Inc., Ophthalmology, Acquisition, Eye, Growth, Biosimilar, Cancer, HOB GmbH & Co KG, CFO, Hand, Development, Security (finance), Generic drug, Pharmaceutical industry, Fine chemical, EU

Press Release // May 18, 2022

Key Points: 
  • Press Release // May 18, 2022
    - Annual result shaped by scheduled investments in FYB202, FYB206 and FYB207
    Munich Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today released its financials for 2021.
  • Due to the increasingly international nature of our business activities, the consolidated financial statements will be prepared in accordance with IFRS (International Financial Reporting Standards) for the first time as of the 2022 half-year financial statements.
  • The separate financial statements of the parent company Formycon AG continue to be prepared and published in accordance with the rules of the German Commercial Code (HGB).
  • Formycon had invested in the development of its own pipeline in the 2021 financial year, resulting in a higher negative annual result compared to previous years.

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Health, Clinical Trials, COVID-19, Mutation, Bulletin, Pasteur Institute, Company, Biomarker, Annual general meeting, Balo concentric sclerosis, General officer, Concept, Patient, Trial of the century, Commercial code, CIO, Hearing loss, Combined, Diagnosis, Email, Health, Hearing, Genetics, Cochlear Limited, Annual, Deafness, Exercise, Mass meeting, Pharmaceutical industry, Medical device

The documents provided for in articles R.22-10-23 of the French Commercial Code, are available for consultation on the companys website mentioned below as of today, the twenty-first day prior to the General Meeting: www.sensorion.com .

Key Points: 
  • The documents provided for in articles R.22-10-23 of the French Commercial Code, are available for consultation on the companys website mentioned below as of today, the twenty-first day prior to the General Meeting: www.sensorion.com .
  • In accordance with articles R.225-83 of the French Commercial Code, documents are available for the shareholders from the time the meeting is convened.
  • For any questions relating to the Annual General Meeting of May 31, 2022, shareholders are invited to send an email to [email protected] .
  • In general, shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website www.sensorion.com .

Artmarket.com: a Warhol at $200 million explained by Artprice in five points

Retrieved on: 
Monday, May 9, 2022
Art, Pablo Picasso, SRD, Campbell Soup Company, Post-War, Thought, Mike Winkelmann, Collection, Art market, Painting, Artprice, Factory, BPI, Color, Commercial code, Founder, Euronext Paris, Shot Marilyns, History, Publication, Larva, Christie's, Sale, Non-fungible token, Museum, Christie, Salvator Mundi, CEO, Fine art, State, Pop art, Ammann, Auction, Interior design, Video game, Andy Warhol, Euroclear, PFP, PRC

Last year, a Picasso painting sold for $103 million, but the record that really impressed was the $69 million for a work by Beeple.

Key Points: 
  • Last year, a Picasso painting sold for $103 million, but the record that really impressed was the $69 million for a work by Beeple.
  • In 2021, his auction turnover reached $348 million, exceeding the $300 million threshold for the first time in six years thanks to some 1,600 works sold worldwide.
  • Estimated between $40 and $60 million, the canvas was finally acquired for $47.4 million.
  • Discover Artmarket and its Artprice department on video: www.artprice.com/video
    Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann.

Artmarket.com: a Warhol at $200 million explained by Artprice in five points

Retrieved on: 
Monday, May 9, 2022
Art, Pablo Picasso, SRD, Campbell Soup Company, Post-War, Thought, Mike Winkelmann, Collection, Art market, Painting, Artprice, Factory, BPI, Color, Commercial code, Founder, Euronext Paris, FS, Shot Marilyns, History, Publication, Larva, Christie's, Sale, Non-fungible token, Museum, Christie, Salvator Mundi, CEO, Fine art, State, Pop art, Ammann, Auction, Interior design, Video game, Andy Warhol, Euroclear, PFP, PRC

Last year, a Picasso painting sold for $103 million, but the record that really impressed was the $69 million for a work by Beeple.

Key Points: 
  • Last year, a Picasso painting sold for $103 million, but the record that really impressed was the $69 million for a work by Beeple.
  • In 2021, his auction turnover reached $348 million, exceeding the $300 million threshold for the first time in six years thanks to some 1,600 works sold worldwide.
  • Estimated between $40 and $60 million, the canvas was finally acquired for $47.4 million.
  • Discover Artmarket and its Artprice department on video: www.artprice.com/video
    Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann.

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

Retrieved on: 
Thursday, May 5, 2022
Common stock, American depositary receipt, Telephone, Jefferies Group, Company, DBV, Council, Form, European Central Bank, Commercial code, Prospectus, Euronext Paris, Shareholder, Person, Form S-3, Madison Avenue, European, ADSS, DBV Technologies, Sale, European Parliament, Central bank, Code, EDGAR, SEC, ADS, Annual, Nasdaq, Security (finance), EU, Euronext

The issuance and the delivery of the new Ordinary Shares will take place on May 6, 2022.

Key Points: 
  • The issuance and the delivery of the new Ordinary Shares will take place on May 6, 2022.
  • A shelf registration statement on Form S-3 (including a prospectus) relating to the ADSs, was filed with the SEC and has been declared effective.
  • Before purchasing ADSs in the offering, prospective investors should read the prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein.
  • Prospective investors may obtain these documents for free by visiting EDGAR on the SECs website at www.sec.gov.

DGAP-News: MPH Health Care AG: Supervisory Board approves 2021 annual financial statements

Retrieved on: 
Wednesday, May 4, 2022
Annual general meeting, Mission statement, Investment, Frankfurt Stock Exchange, Supervisory board, NAV, Commercial code, Annual report, Board of directors, ISIN, IFRS, MPH, Sale, Open Market, HGB, Annual, Acquisition, Security (finance), Health insurance

Berlin, 4 May 2022: At its meeting yesterday, the Supervisory Board of MPH Health Care AG (ISIN: DE000A289V03) approved the annual financial statements of MPH Health Care (individual financial statements in accordance with the German Commercial Code (HGB) and consolidated financial statements in accordance with IFRS), which were issued with an unqualified audit certificate.

Key Points: 
  • Berlin, 4 May 2022: At its meeting yesterday, the Supervisory Board of MPH Health Care AG (ISIN: DE000A289V03) approved the annual financial statements of MPH Health Care (individual financial statements in accordance with the German Commercial Code (HGB) and consolidated financial statements in accordance with IFRS), which were issued with an unqualified audit certificate.
  • The Annual Report 2021 of MPH Health Care AG will be published on 24 May 2022.
  • About MPH Health Care AG:
    MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market.
  • MPH Health Care AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

Retrieved on: 
Tuesday, May 3, 2022
Biotechnology, Pharmaceutical, Health, Oncology, 808, Antibody, State Street, U.S. Securities and Exchange Commission, Immune system, Novo Nordisk, Telephone, Million Pound Menu, LLC, Company, Securities Act of 1933, Form, Attention, Time, Tumor microenvironment, SEC Rule 144A, Patient, Security (finance), Commercial code, Regulation D, Prospectus, Program, Euronext Paris, Cancer, SVB, ADSS, IPH, Sale, Sanofi, Code, EDGAR, Article One, IPHA, SEC, AstraZeneca, Annual general meeting, Bristol Myers Squibb, Research, Annual, ATM, Vaccine, EU, Nasdaq, Shareholder, MD, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (SEC) relating to an At-The-Market (ATM) program.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (SEC) relating to an At-The-Market (ATM) program.
  • The ATM program is presently intended to be effective unless terminated in accordance with the sales agreement or the maximum amount of the program has been reached.
  • Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Retrieved on: 
Monday, May 2, 2022
The Annual Report, Annual report, Form S-3, Madison Avenue, Skin, SEC, Program, Immune system, Peanut, Company, Press release, Immunotherapy, Patient, Risk, Prospectus, European Parliament, Code, ADS, Research, Annual, ATM, AMF, Cosmetics, U.S. Securities and Exchange Commission, Telephone, Time, Commercial code, Ticker, European, Federal Reserve Bank of New York, ISIN, Sale, Annual general meeting, Jefferies Group, Council, Form, URD, Jefferies, Federal Reserve Bank, Special-purpose acquisition company, Shareholder, ADSS, DBV Technologies, EDGAR, Security (finance), DBV, Euronext, EU, Euronext Paris, Nasdaq

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Global Select Market: DBVT) (the Company), a clinical-stage biotechnological company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) relating to an At-The-Market offering (the ATM Program).

Key Points: 
  • DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Global Select Market: DBVT) (the Company), a clinical-stage biotechnological company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) relating to an At-The-Market offering (the ATM Program).
  • Viaskin is based on epicutaneous immunotherapy, or EPIT, DBV Technologies method of delivering biologically active compounds to the immune system through intact skin.
  • This press release contains forward-looking statements, including statements regarding DBV Technologies proposed securities offering and its intended use of proceeds.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

DGAP-News: Dolkam Suja a.s.: CONVOCATION OF ORDINARY GENERAL MEETING

Retrieved on: 
Thursday, April 28, 2022
Article, Association, Publishing, PhilPost Postal ID, Bratislava, Companies Act 2006, OGM, BOD, SEC, District court, ID, CC, Para, Person, Company, Internet, XI, Exercise, Coll, MTV Europe Music Award for Best Czech & Slovak Act, Risk, Block B, Commercial code, SB, Proxy, AOA, Art, Security (finance), Holding company

Shareholder has the right to participate in and vote at general meeting.

Key Points: 
  • Shareholder has the right to participate in and vote at general meeting.
  • A shareholder attends the general meeting personally or represented by proxy holder based on a written proxy pursuant to Sec.
  • Template of the written proxy which can be used for proxy voting is attached to this convocation.
  • 190a CC nor the shareholders' participation in and voting at the general meeting by electronic means pursuant to Sec.